معرفی
James V. Freeman, MD, MPH, MS, is a Professor of Medicine (Cardiovascular Medicine) at Yale School of Medicine, serving as Director of Cardiac Electrophysiology for Yale New Haven Health and Director of the Yale Atrial Fibrillation Program. He specializes in treating complex arrhythmias, left atrial appendage occlusion, and implantable cardiac devices. His research focuses on comparative effectiveness and outcomes of therapies for atrial fibrillation, ventricular arrhythmias, and heart failure, funded by NIH and professional organizations.
Education & Training:
- MD: Johns Hopkins University School of Medicine (2003)
- MPH: Johns Hopkins Bloomberg School of Public Health (Biostatistics/Epidemiology)
- MS: Stanford University School of Medicine (Health Services Research)
Research Interests: Atrial fibrillation management, device-based therapies, stroke prevention, and health equity in cardiovascular care. Key areas include left atrial appendage occlusion (LAAO) outcomes, racial disparities in device use, and procedural volume impacts.
Articles Overview: Recent work highlights advancements in LAAO technologies (e.g., Amulet, WATCHMAN FLX), anticoagulation strategies post-LAAO, and disparities in patient outcomes. His studies leverage large registries (NCDR) to assess real-world efficacy and safety.
Labs/Teams: Leads the Yale Atrial Fibrillation Program and collaborates with institutions like the Center for Outcomes Research & Evaluation (CORE) to advance translational research in cardiac electrophysiology.
